👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

IQVIA shares target cut but keeps buy rating amid 2025 headwinds

EditorNatashya Angelica
Published 12/11/2024, 09:50 AM
IQV
-

On Wednesday, TD Cowen maintained a Buy rating on IQVIA Holdings (NYSE: NYSE:IQV) shares but reduced the price target from $255.00 to $250.00. The analyst provided a cautiously optimistic view on the company's long-term earnings potential, noting potential challenges in the near term but expressing confidence in IQVIA's capabilities to navigate the market.

IQVIA, known for its extensive services in drug development, technology solutions, and laboratory services, has been recognized for its ability to withstand various market pressures.

The analyst highlighted that the company is expected to see relief from several recent challenges over the next year. This includes a recovery in Therapeutic Area Strategy (TAS), a peak in the shift to Functional Service Provider (FSP) models, and the completion of strategic pricing discussions with partners.

Despite near-term headwinds anticipated in 2025, with implied earnings per share (EPS) ranging between $11.66 and $12.21 versus a consensus of $12.05, the company's long-term EPS growth rates are projected to be in the high single digits to low double digits. This forecast is viewed as potentially conservative by the analyst.

IQVIA's management has indicated that a large portion of the pharmaceutical industry's cost-cutting measures should be completed by the first half of 2025. This is expected to ease some of the pressures the company has been facing.

The analyst emphasized that IQVIA's strong track record in executing its business strategy positions it favorably for when the demand environment improves. However, the firm underscored that execution in 2025 will be crucial for maintaining confidence in the company's long-term outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.